caffeic acid phenethyl ester has been researched along with 1,3-dipropyl-8-cyclopentylxanthine in 2 studies
| Studies (caffeic acid phenethyl ester) | Trials (caffeic acid phenethyl ester) | Recent Studies (post-2010) (caffeic acid phenethyl ester) | Studies (1,3-dipropyl-8-cyclopentylxanthine) | Trials (1,3-dipropyl-8-cyclopentylxanthine) | Recent Studies (post-2010) (1,3-dipropyl-8-cyclopentylxanthine) |
|---|---|---|---|---|---|
| 840 | 1 | 469 | 1,301 | 1 | 165 |
| Protein | Taxonomy | caffeic acid phenethyl ester (IC50) | 1,3-dipropyl-8-cyclopentylxanthine (IC50) |
|---|---|---|---|
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.0051 | |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | 0.0038 | |
| Adenosine receptor A2a | Homo sapiens (human) | 0.2033 | |
| Adenosine receptor A2b | Homo sapiens (human) | 0.0234 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
2 other study(ies) available for caffeic acid phenethyl ester and 1,3-dipropyl-8-cyclopentylxanthine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |